Corbus Pharmaceuticals Holdings, Inc. Litigation Settlement, Expense
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Litigation Settlement, Expense of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2024-03-12
- Corbus Pharmaceuticals Holdings, Inc. litigation settlement, expense for the quarter ending 2023-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. litigation settlement, expense for the quarter ending 2023-09-30 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. litigation settlement, expense for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. litigation settlement, expense for the quarter ending 2023-03-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. litigation settlement, expense for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. litigation settlement, expense for fiscal 2022 was $5.00M.
- Corbus Pharmaceuticals Holdings, Inc. litigation settlement, expense for fiscal 2021 was $0.00.
| Period end | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 10-K · filed 2024-03-12 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $5.00M derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $5.00M derived: sum of 3 quarters · filed 2024-03-12 | $5.00M 10-K · filed 2024-03-12 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $5.00M derived: sum of 2 quarters · filed 2023-11-07 | $5.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $5.00M 10-Q · filed 2023-08-08 | $5.00M 10-Q · filed 2023-08-08 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |